Ensysce Biosciences completes enrollment of PF614-MPAR-101 Phase 1 study

Ensysce Biosciences announced the completion of enrollment in the final stage of the Phase 1 study, PF614-MPAR-101. This study was conducted by Dr. Maria Bermudez MD, at Quotient Sciences, Miami, Florida. PF614-MPAR is the overdose protection derivative of the Ensysce lead product PF614 and holds the promise of protecting against multiple forms of abuse and overdose, an industry first. The added layer of overdose protection is made possible by combining PF614 with a trypsin inhibitor, nafamostat, to prevent overdose if too many pills are swallowed. The combination product, PF614-MPAR, is designed to provide optimal pain relief at prescribed doses yet limit accidental or intentional overdose by ‘shutting down’ opioid release if too much active drug is consumed.